- Home
- ADAG vs SPRO Comparison
ADAG vs SPRO Comparison
Compare ADAG & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAG
- SPRO
- Stock Information
- Founded
- ADAG 2011
- SPRO 2013
- Country
- ADAG China
- SPRO United States
- Employees
- ADAG N/A
- SPRO N/A
- Industry
- ADAG Biotechnology: Pharmaceutical Preparations
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- ADAG Health Care
- SPRO Health Care
- Exchange
- ADAG Nasdaq
- SPRO Nasdaq
- Market Cap
- ADAG 110.8M
- SPRO 110.9M
- IPO Year
- ADAG 2021
- SPRO 2017
- Fundamental
- Price
- ADAG $1.95
- SPRO $2.13
- Analyst Decision
- ADAG Strong Buy
- SPRO Buy
- Analyst Count
- ADAG 3
- SPRO 4
- Target Price
- ADAG $7.67
- SPRO $5.00
- AVG Volume (30 Days)
- ADAG 60.8K
- SPRO 308.6K
- Earning Date
- ADAG 08-12-2025
- SPRO 11-13-2025
- Dividend Yield
- ADAG N/A
- SPRO N/A
- EPS Growth
- ADAG N/A
- SPRO N/A
- EPS
- ADAG N/A
- SPRO N/A
- Revenue
- ADAG $103,204.00
- SPRO $48,576,000.00
- Revenue This Year
- ADAG $7,411.34
- SPRO N/A
- Revenue Next Year
- ADAG $28.29
- SPRO N/A
- P/E Ratio
- ADAG N/A
- SPRO N/A
- Revenue Growth
- ADAG N/A
- SPRO N/A
- 52 Week Low
- ADAG $1.33
- SPRO $0.51
- 52 Week High
- ADAG $3.16
- SPRO $3.22
- Technical
- Relative Strength Index (RSI)
- ADAG 44.56
- SPRO 60.07
- Support Level
- ADAG $1.85
- SPRO $1.84
- Resistance Level
- ADAG $2.06
- SPRO $2.05
- Average True Range (ATR)
- ADAG 0.11
- SPRO 0.08
- MACD
- ADAG -0.01
- SPRO 0.03
- Stochastic Oscillator
- ADAG 26.08
- SPRO 85.71
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.